Home > News > Midatech nanoparticles heading for the clinic in Q1 2008
May 14th, 2007
Midatech nanoparticles heading for the clinic in Q1 2008
Midatech, the UK group exploring the therapeutic and diagnostic applications of nanoparticles as drug delivery vehicles, scaffolds for synthetic vaccines or antibiotics and non-invasive imaging agents, aims to put its first product into clinical trials in the first quarter of 2008.
This will be multivalent antibiotics delivered on nanoparticles, said Midatech's Storme Thornicroft. The group's listed pipeline includes a project coded MTL 201 that involves antibiotics for the treatment of the 'superbug' methicillin-resistant Staphylococcus aureus (MRSA).
Researchers create vaccine for dust-mite allergies Main Page Content: Vaccine reduced lung inflammation to allergens in lab and animal tests July 22nd, 2014
NIST shows ultrasonically propelled nanorods spin dizzyingly fast July 22nd, 2014
SentiMag® Now Available in Australia and New Zealand July 21st, 2014
More than glitter: Scientists explain how gold nanoparticles easily penetrate cells, making them useful for delivering drugs July 21st, 2014
Silicene Labs Announces the Launch of Patent-Pending, 2D Materials Composite Index™ : The Initial 2D Materials Composite Index™ for Q2 2014 Is: 857.3; Founders Include World-Renowned Physicist and Seasoned Business and IP Professionals July 24th, 2014
Iranian Scientists Produce Transparent Nanocomposite Coatings with Longer Lifetime July 24th, 2014
Deadline Announced for Registration in 7th Int'l Nanotechnology Festival in Iran July 23rd, 2014
A Crystal Wedding in the Nanocosmos July 23rd, 2014